Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 55.7% in May

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) was the target of a large increase in short interest in May. As of May 31st, there was short interest totalling 4,250,000 shares, an increase of 55.7% from the May 15th total of 2,730,000 shares. Currently, 4.9% of the company's stock are short sold. Based on an average trading volume of 1,350,000 shares, the days-to-cover ratio is presently 3.1 days.

Immunic Stock Down 4.6%

NASDAQ IMUX traded down $0.04 during mid-day trading on Friday, hitting $0.80. The stock had a trading volume of 960,155 shares, compared to its average volume of 886,213. Immunic has a 52-week low of $0.56 and a 52-week high of $2.11. The company has a market cap of $77.12 million, a price-to-earnings ratio of -0.65 and a beta of 1.48. The company has a 50 day simple moving average of $0.95 and a 200 day simple moving average of $1.04.

Immunic (NASDAQ:IMUX - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.25) EPS for the quarter, meeting analysts' consensus estimates of ($0.25). As a group, equities analysts anticipate that Immunic will post -0.94 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on IMUX shares. William Blair reissued an "outperform" rating on shares of Immunic in a research report on Friday, May 16th. Wall Street Zen cut Immunic from a "hold" rating to a "sell" rating in a research report on Thursday, March 20th. D. Boral Capital reaffirmed a "buy" rating and set a $10.00 price objective on shares of Immunic in a research report on Thursday, June 5th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Immunic in a research report on Thursday, May 1st. Finally, B. Riley reaffirmed a "buy" rating and set a $5.00 price objective (down from $6.00) on shares of Immunic in a research report on Friday, May 23rd. One research analyst has rated the stock with a sell rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Immunic presently has an average rating of "Buy" and a consensus price target of $11.60.

Institutional Investors Weigh In On Immunic

Several hedge funds have recently made changes to their positions in the business. 683 Capital Management LLC boosted its holdings in Immunic by 2.2% in the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company's stock valued at $700,000 after acquiring an additional 15,349 shares during the last quarter. Bridgeway Capital Management LLC boosted its holdings in Immunic by 11.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock valued at $215,000 after acquiring an additional 22,200 shares during the last quarter. Focus Partners Wealth raised its position in Immunic by 1.1% in the fourth quarter. Focus Partners Wealth now owns 2,168,353 shares of the company's stock valued at $2,168,000 after purchasing an additional 23,610 shares during the period. Invesco Ltd. purchased a new position in Immunic in the fourth quarter valued at about $37,000. Finally, Barclays PLC purchased a new position in Immunic in the fourth quarter valued at about $84,000. Institutional investors and hedge funds own 51.82% of the company's stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.